Amorepacific Group has developed a chipless wireless electronic skin that accurately analyzes and measures skin conditions in collaboration with professor Kim Jeehwan of the Massachusetts Institute of Technology (MIT).
The technology, developed after four years of joint research, does away with the use of heavy equipment.
The scholarly publication Science reported the results of this breakthrough.
By making it simpler to identify the skin ailments of people who work in specialized surroundings while being exposed to cold, heat, or dryness, Amorepacific anticipates that this technology will aid in the development of customized functional cosmetics.
Major brands like Sulwhasoo from Amorepacific will leverage the technology developed from this study.
Clinical skin research demands the use of expensive diagnostic tools in addition to sustaining a constant temperature and humidity level.
As a result, there aren't many results from skin research that were obtained in unique circumstances.


Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds
Is dark chocolate healthier than milk chocolate? 2 dietitians explain
Gold Prices Drop Amid Iran Peace Talk Uncertainty and Stronger Dollar
Yes, government influences wages – but not just in the way you might think
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 



